Dr Joline Lim is a consultant and clinician scientist at the National University Cancer Institute, Singapore. Her primary clinical and research interests are in breast oncology and early phase clinical trials, with a special focus on the development of novel anti-cancer therapeutic agents and biomarkers.
Dr Lim graduated from the Yong Loo Lin School of Medicine, National University Singapore in 2007, and commenced her basic specialist training in NUH. This phase of training, which saw her conferred the Membership of the Royal College of Physicians (United Kingdom) in Internal Medicine in 2010, culminated in her being appointed as the Chief Resident of the Internal Medicine Residency Program. She subsequently pursued a year of research training under Professor Daniel Tenen and Dr Li Chai at Beth Israel Deaconess Medical Centre / Brigham and Women Hospital, Harvard Medical School, Boston. Upon returning to Singapore, she completed her advanced specialist training in medical oncology at the National University Cancer Institute, Singapore, where she was appointed as the Senior Chief Resident of Medical Oncology and was admitted as a Fellow of the Academy of Medicine, Singapore (Medical Oncology) in 2015.
Dr Lim has a keen interest in translational research involving novel anti-tumour therapies including molecular targeted agents and immunotherapies, and the application of emerging predictive and pharmacodynamic biomarkers. To pursue this interest further, she has completed advanced training in early phase drug development at the Royal Marsden Hospital in the United Kingdom as a National Medical Research Council Research Training Fellow. Her efforts in novel combination strategies in breast cancer led to her being awarded the Conquer Cancer Foundation of ASCO Merit Award in 2017. She is actively involved in multi-centred international clinical trials, and is the principal and co-investigator for translational research grants involving new biomarker development. Her peer-reviewed publications to date include the New England Journal of Medicine, Cancer Discovery, and Annals of Oncology.
Her past leadership positions include:
1. Emerging biomarkers for programmed death-1 pathway cancer therapy.J SJ Lim, R Sundar, M Chenard-Poirier, J Lopez, T A Yap. Biomark Med 2017; 11(1):53-67.
2. Towards precision medicine in the clinic : from biomarker discovery to novel therapeutics. DC Collins, R Sundar,J SJ Lim, T A Yap. Trends Pharmacol Sci 2017; 38(1):25-40.
3. Outcomes after neoadjuvant chemotherapy in Asian breast cancer patients. LY Lim, H Miao,J SJ Lim, SC Lee, N Bhoo-Pathy, CH Yip, NA Taib, P Chan, EY Tan, SH Lim, GH Lim, E Woo, YS Tan, JA Lee, M Wong, PH Tan, KW Ong, FY Wong, YS Yap, M Hartman. Cancer Medicine 2017;6(1):173-185.
4. CDK4/6 inhibitors: Promising opportunities beyond breast cancer.J SJ Lim, N C Turner, T A Yap. Cancer Discov 2016; 6(7): 697-9.
5. Emerging strategies for the treatment of advanced small cell lung cancer.J SJ Lim, D Collins, T A Yap. J Thorac Dis 2016; 8(10):E1249-53.
6. Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence.J SJ Lim, R A Soo. Ther Adv Respir Dis 2016; 10(5): 444-54.
7. Tumour pharmacodynamics and circulation cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib. A LA Wong*,J SJ Lim*, A Sinha, A Gopinathan, R Lim, CS Tan, T Soh, S Venkatesh, C Titin, NS Sapari, SC Lee, WP Yong, D SP Tan, B Pang, TT Wang, YK Zee, R Soong, Z Trnkova, C Lathia, JP Thiery, S Wilhelm, M Jeffers, BC Goh. J Transl Med 2015, 12:13:57.
8. Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. AL Wong, RA Soo, DS Tan, SC Lee,J SJ Lim, PC marban, LR Kong, YJ Lee, LZ Wang, WL Thuya, R Soong, MQ Yee, TM Chin, MT Cordero, BR Asuncion, B Pang, S Pervaiz, JL Hirpara, Asinha, WW Xu, M Yuasa, T Tsunoda, M Motoyama, T Yamauchi, BC Goh. Annals of Oncology 2015; 26(5):998-1005.
9. Understanding intra-tumor heterogeneity – the next Holy Grail of cancer therapeutics?J SJ Lim, SC Lee. Ann Acad Med Singapore 2014;43(2)1-2.
10. Oncofetal protein SALL4 predicts an aggressive hepatocellular carcinoma subtype. KJ Yong, C Gao,J SJ Lim, B Yan, H Yang, T Dimitrov, A Kawasaki, CW Ong, S Srivastava, X Tian, RT Poon, ST Fan, JM Luk, YY Dan, M Salto-tellez, L Chai, DG Tenen. N Engl J Med 2013; 368(24):2266-76.
